EGFR and non-small cell lung carcinoma: In May 2024, China approved AK112 in combination with chemotherapy (pemetrexed + carboplatin) for patients with locally advanced or metastatic non-sq-NSCLC who are EGFR mutation-positive and have progressed after treatment with EGFR TKIs (158).